Current treatment options: impact of cytogenetics on the course of myelodysplasia.

Current treatment options: impact of cytogenetics on the course of myelodysplasia. Research Abstract Details 

Research Abstract Table of Contents

Jump to the:

Current treatment options: impact of cytogenetics on the course of myelodysplasia. Abstract Text:

Naomi Galili,Jan Cerny,Azra Raza,Naomi Galili,Jan Cerny,Azra Raza,

The heterogeneity of myelodysplastic syndromes (MDS) has driven the search for unifying biologic and clinical features that would stratify patients into distinct prognostic and therapeutic subgroups. Cytogenetics has been shown to impact the course of myelodysplasia. Despite the presence of non-random cytogenetic abnormalities in approximately 50% of MDS patients, it is significant that only a proportion of metaphases may contain the abnormality. Clonality studies however show that the karyotypically normal metaphases are still part of the MDS clone. This would suggest that the chromosomal abnormality may not be the initiating lesion in MDS, and that the gross karyotypic changes represent clonal evolution in a genetically unstable population. Yet, as will be described below, specific cytogenetic abnormalities are associated with clinically and biologically distinct forms of the disease, most notable in the response of del(5q) patients to lenalidomide. One possible explanation for the appearance of non-random mutational events could relate to the interaction of MDS cells with their microenvironment. Whatever the initiating lesion in the MDS stem cell, the end result is a clonal expansion where the marrow becomes populated by the monoclonal progeny of this cell. Interaction of these cells with a microenvironment which has been shown to be rich in pro-apoptotic cytokines such as tumor necrosis factor alpha (TNFa), leads to increased genetic instability. Hypoxia mediated decrease in DNA repair enzymes could further accelerate mutational events culminating in accumulation of multiple chromosomal abnormalities. Some of these chromosomal changes are associated with increased sensitivity to specific drugs. Lenalidomide has shown a high degree of efficacy in MDS patients with del(5q), although the target for the drug is unknown since a small but significant subset of MDS patients without del(5q) abnormality also respond to the drug. In contrast, the molecular target for imatinib mesylate is known; mutations in tyrosine kinase receptor family of genes found in patients with t(5;12) and del(4q12) make these individuals sensitive to the drug. Patients with isolated trisomy 8 have an immune component to the disease phenotype which can be targeted by cyclosporine and or anti-thymocyte globulin (ATG), especially in the presence of a PNH (paroxysmal nocturnal hemoglobinurea) clone. In the absence of these specific cytogenetic abnormalities described above, the two FDA approved hypomethylating agents 5 azacytidine and decitabine should be considered as therapeutic alternatives.

Current treatment options: impact of cytogenetics on the course of myelodysplasia. Publishing Authors By Initials

N Galili,J Cerny,A Raza,N Galili,J Cerny,A Raza,

For similar abstracts research abstracts see: abstracts research

PUBMED ID PMID:

MEDLINE DATE:

Current treatment options: impact of cytogenetics on the course of myelodysplasia. Journal Published:

PUBLICATION TYPE: Journal Article

Journal: Current treatment options in oncology

VOLUME: 8

Page Numbers: 117-28

Journal Abbreviation:

ISSN: 1527-2729

DAY: 15

MONTH: Apr

YEAR: 2007

Current treatment options: impact of cytogenetics on the course of myelodysplasia. Information

Number of References:

LANGUAGE: eng

NlmUniqueID: 100900946

Current treatment options: impact of cytogenetics on the course of myelodysplasia. Keywords Mesh Terms:

KEYWORDS:

MESH TERMS:

Chemical & Substance for Abstract: Current treatment options: impact of cytogenetics on the course of myelodysplasia. Information

Substance Name:

Registry Number:

Grant and Affiliation Information for Current treatment options: impact of cytogenetics on the course of myelodysplasia.

AFFILIATION: Radhey Khanna MDS Center, Division of Hematology, University of Massachusetts Medical Center, 364 Plantation Street, Worcester, MA 01605, USA.

Country: United States

AGENCY:

GRANT:

ACRONYM:

MEDLINETA: Curr Treat Options Oncol

REFSOURCE:

DATABASENAME:

ACCESSION NUMBER:

Number Hits: 0

Current treatment options: impact of cytogenetics on the course of myelodysplasia Related Publications

• 'I just thought it was normal aches and pains': a qualitative study of decision-making processes in patients with early rheumatoid arthritis.
• A child with acute appendicitis.
• An erythroid differentiation signature predicts response to lenalidomide in myelodysplastic syndrome.
• Beliefs about medicines in patients with rheumatoid arthritis and systemic lupus erythematosus: a comparison between patients of South Asian and White British origin.
• Benign fibrous histiocytoma of the rib.
• Comment on: Delay in presentation to primary care physicians is the main reason why patients with rheumatoid arthritis are seen late by rheumatologists: reply.
• Comparison of two methods (precipitation manual and fully automated enzymatic) for the analysis of HDL and LDL cholesterol.
• Computer audiogram.
• Current treatment options: impact of cytogenetics on the course of myelodysplasia.
• Disorders of sex development (DSDs), their presentation and management in different cultures.
• Eosinophilia with FIP1L1-PDGFRA fusion in a patient with chronic myelomonocytic leukemia.
• Facilitating treatment of anxiety disorders in patients with comorbid medical illness.
• Immunomodulatory drugs in myelodysplastic syndromes.
• In situ end labelling of DNA to detect apoptotic cell death in a variety of human tumours.
• In vitro assessment of drug sensitivity in acute nonlymphocytic leukemia.
• Interferon alpha 2a in patients of chronic hepatitis C.
• Localized lesions in secondary syphilis.
• Myocardial revascularization.
• Power Doppler sonography of breast cancer: does vascularity correlate with node status or lymphatic vascular invasion?
• Re: Obtaining previous mammograms for comparison.
• Silent myocardial ischemia.
• Studies on flammability of clothing of burn victims, changes therein and their wearability after a borax rinse.
• Studies on flammability of clothing of burn victims, changes therein and their wearability after a borax rinse.
• The assessment of risk factors for postoperative nausea and vomiting.
• The efficacy of Silybum marianum (L.) Gaertn. (silymarin) in the treatment of type II diabetes: a randomized, double-blind, placebo-controlled, clinical trial.
• The role of family configuration in early childhood intellectual development in the context of an extended family system in Pakistan.
• Validation of a prediction rule for disease outcome in patients with recent-onset undifferentiated arthritis: Moving toward individualized treatment decision-making.